Hemlibra ® 30 mg/1 ml Solution

    Hemlibra ® 30 mg/1 ml Solution

    S4

    API: Emicizumab | Company: Roche Products

    1. What Hemlibra is and what it is used for

    What Hemlibra is
    Hemlibra belongs to a group of medicines called “monoclonal antibodies”. Monoclonal antibodies are a type of protein that recognises and binds to a target in the body.

    What Hemlibra is used for
    Hemlibra is used for treating patients of all ages with:

    • either haemophilia A who have developed factor VIII inhibitors
    • or with severe haemophilia A who have not developed factor VIII inhibitors (the FVIII blood level is less than 1 %).

    Haemophilia A is an inherited condition caused by a lack of factor VIII, an essential substance required for blood to clot and stop any bleeding. Hemlibra prevents bleeding or reduces bleeding episodes in people with this condition. Some patients with haemophilia A can develop factor VIII inhibitors (antibodies against factor VIII) which stop the replacement factor VIII from working.

    How Hemlibra works
    Hemlibra restores the function of missing factor VIII that is needed for effective blood clotting. Its structure is different from factor VIII, therefore Hemlibra is not affected by factor VIII inhibitors.

    2. What you need to know before you use Hemlibra

    Hemlibra should not be administered to you:

    • If you are hypersensitive (allergic) to emicizumab or any of the other ingredients of Hemlibra.

    Warnings and precautions

    Before you start using Hemlibra, it is very important you talk to your doctor about when and how to use “bypassing agents” while receiving Hemlibra, as this may differ from before. Examples of bypassing agents include “activated prothrombin complex concentrate” (aPCC, also called FEIBA) and “recombinant FVIIa” (rFVIIa, also called NovoSeven). Serious and potentially life-threatening side effects have been observed when aPCC (FEIBA) was used in patients who were also receiving Hemlibra. Be aware of the potentially serious side effects of using activated prothrombin complex concentrate (aPCC) (FEIBA) while receiving Hemlibra (see “Possible side effects”).

    • Destruction of red blood cells (thrombotic microangiopathy) - thrombotic microangiopathy is a serious and potentially life-threatening condition, - when people have thrombotic microangiopathy, the lining of the blood vessels can be damaged and blood clots may develop in small blood vessels. This can cause damage to the kidneys and/or other organs, - it is important to know the symptoms of thrombotic microangiopathy, in case you develop the condition (see “Possible side effects” for a list of symptoms). Stop using Hemlibra and activated prothrombin complex concentrate (aPCC) (FEIBA), and talk to a doctor immediately if you or your caregiver notices any symptoms of thrombotic microangiopathy.
    • Blood clots (thromboembolism) - blood clots may form. A blood clot can block blood vessels and may be life-threatening - it is important to know the symptoms of blood clots, in case clots develop (see “Possible side effects” for a list of symptoms) Stop using Hemlibra and activated prothrombin complex concentrate (aPCC) (FEIBA), and talk to a doctor immediately if you or your caregiver notices any symptoms of blood clots.

    Antibody formation (immunogenicity)

    In uncommon cases, you can develop antibodies to this medicine and it may then stop working for you. - you may notice that bleeding is not being controlled with your prescribed dose of this medicine. Talk to a doctor immediately if you or your caregiver notices that Hemlibra has stopped working for you (e.g. an increase in bleeds). Your doctor may need to change your treatment if Hemlibra stops working for you.

    Children below the age of 1 year

    In children less than one year of age, the blood system is still developing. If your child is less than one year old, your doctor may prescribe Hemlibra only after carefully weighing the expected benefits and risks of using this product.

    Other medicines and Hemlibra

    Always tell your healthcare professional if you are taking any other medicine. (This includes complementary or traditional medicines).

    • Using a bypassing agent while receiving Hemlibra - Before you start using Hemlibra, talk to your doctor and carefully follow their instructions regarding when to use a bypassing agent and the dose and schedule you should use. Hemlibra increases the ability of your blood to clot. Therefore, the dose of bypassing agent required may be lower than the dose you used prior to starting Hemlibra.
    • Avoid using activated prothrombin complex concentrate (aPCC) (FEIBA) unless no other treatment options are available. However, if aPCC (FEIBA) is required, talk to your doctor in case you feel you need more than 50 units/kg of aPCC (FEIBA) total. For more information on using aPCC (FEIBA) while receiving Hemlibra, see “What you need to know before you use Hemlibra”, be aware of the potentially serious side effects of using aPCC (FEIBA) while receiving Hemlibra.

    Laboratory tests

    Tell your doctor if you are using Hemlibra before you have laboratory tests that measure how well your blood is clotting. This is because the presence of Hemlibra in the blood may interfere with some of these laboratory tests, leading to inaccurate results.

    Pregnancy and breastfeeding

    If you are pregnant, if you think you are pregnant, if you are planning to have a baby or breastfeeding your baby, please consult your doctor, pharmacist or other healthcare professional for advice before being given Hemlibra.

    • Do not use Hemlibra if you are pregnant. Your doctor will discuss the risk to your baby.
    • You should use an effective method of birth control (contraception) during treatment with Hemlibra and for 6 months after your last injection of Hemlibra.
    • Do not breastfeed your baby while on treatment with Hemlibra.

    Driving and using machines

    Hemlibra is not likely to affect your ability to drive or use machines.

    3. How to use Hemlibra

    A medical practitioner qualified to care for patients with haemophilia will start you on treatment with Hemlibra. Always use Hemlibra exactly as your doctor has instructed you. You should check with your doctor or pharmacist if you are unsure.

    Each time you use Hemlibra, record the name and batch number of the medicine.

    How much Hemlibra to use

    First dose
    Weeks 1 to 4: The dose is 3 milligrams for every 1 kilogram you weigh, injected under the skin (subcutaneously) once a week.

    Maintenance doses

    From week 5 and onwards: The dose of Hemlibra is dependent on your weight and your doctor should tell you how much to inject. The dose is either:

    • 1,5 mg/kg once weekly, or
    • 3 mg/kg every two weeks, or
    • 6 mg/kg every four weeks

    How Hemlibra is given

    If you or your caregiver gives an injection of Hemlibra, you must carefully read and follow the instructions under “Instructions for use” below.

    • Hemlibra is given by injection under the skin (subcutaneously)
    • Your doctor or nurse will show you and/or your caregiver how to inject Hemlibra
    • Once you and/or your caregiver have been trained, you should be able to inject this medicine at home, by yourself or with the help of a caregiver
    • Do not inject Hemlibra into a vein or muscle. To correctly insert the needle under the skin, pinch a fold of loose skin at the clean injection site with your free hand. Pinching the skin is important to ensure that you inject under the skin (into fatty tissue) but not any deeper (into muscle). Injecting into a muscle could result in an uncomfortable injection
    • Prepare and give the injection under clean and germ-free conditions using “aseptic technique”. You will be given more information about this by your doctor or nurse
    • Before using Hemlibra, check the solution for particles or discolouration. The solution should be colourless to slightly yellow. Do not use Hemlibra if you notice that it is cloudy, discoloured, or contains visible particles.

    Where to inject Hemlibra

    • Your doctor will show you and/or your caregiver which areas of the body should be injected with Hemlibra,
    • The recommended places to give an injection are: the front of the waist (lower abdomen), upper outer arms, or the front of the thighs. Only give an injection in the recommended places,
    • Each time you or your caregiver gives an injection, use a different area of the body to the one you used before, using one of the recommended places (front of the waist, upper outer arms, or the front of the thighs),
    • Do not give injections where the skin is red, bruised, tender, hard, or areas where there are moles or scars,
    • When using Hemlibra, other medicines injected under the skin should be given in a different area.

    Using syringes and needles

    • A syringe, a transfer needle with filter, a transfer needle, a vial adaptor or vial adaptor with filter and an injection needle are needed to withdraw the Hemlibra solution from the vial into the syringe and inject it under the skin,
    • Syringes, transfer needles with filter, transfer needles, vial adaptors, vial adaptors with filter and injection needles are not provided in this pack. For more information, see “What Hemlibra looks like and contents of the pack”, what is needed for Hemlibra administration and is not contained in this pack,
    • Make sure that you use a new injection needle for each injection and dispose of it after a single use,
    • A 1 mL syringe should be used for an injection up to 1 mL of Hemlibra solution.
    • A 2 to 3 mL syringe should be used for an injection greater than 1 mL and up to 2 mL of Hemlibra solution.
    • When used together with a vial adaptor, a low dead space plunger syringe must be used.

    Your doctor will tell you how long your treatment with Hemlibra will last. Do not stop treatment without consulting with your doctor. If you have the impression that the effect of Hemlibra is too strong or too weak, tell your doctor or pharmacist.

    Use in children and adolescents

    Hemlibra can be used in children and adolescents of all ages (for the recommended dose, see “How to use Hemlibra”). If a child would like to self-inject the medicine, the child’s healthcare provider and the parent or caregiver should agree on whether it is appropriate for them to do so. Self-injection for children below the age of 7 years is not recommended.

    If you take more Hemlibra than you should

    In the event of overdosage, consult your doctor or pharmacist. If neither is available, contact the nearest hospital or poison control centre. If you or your caregiver uses more Hemlibra than you are supposed to, tell your doctor immediately. This is because you may be at risk of developing side effects such as blood clots.

    If you forget to take Hemlibra

    If you forget your scheduled weekly injection, inject the forgotten dose as soon as possible approximately 24 hours before the day of the next scheduled dose. Then, continue to inject the medicine once a week as scheduled. Do not inject a double dose to make up for a forgotten dose.

    If you stop taking Hemlibra

    Do not stop using Hemlibra without talking to your doctor. If you stop using Hemlibra, you may no longer be protected against bleeding. If you have any further questions on the use of Hemlibra, ask your doctor, pharmacist or nurse.

    4. Possible side effects

    Hemlibra can have side effects. Not all side effects reported for Hemlibra are included in this leaflet. Should your general health worsen or if you experience any untoward effects while taking Hemlibra please consult your doctor, pharmacist or healthcare professional for advice.

    Serious side effects of using activated prothrombin complex concentrate (aPCC) (FEIBA) while receiving Hemlibra

    Stop using Hemlibra and aPCC (FEIBA) and talk to a doctor immediately if you or your caregiver notices any of the following side effects:

    • Destruction of red blood cells (thrombotic microangiopathy): - confusion - weakness, - swelling of arms and legs, - yellowing of skin and eyes, - vague abdominal or back pain, feeling sick (nausea), - being sick (vomiting) or - urinating less These symptoms may be signs of thrombotic microangiopathy.
    • Blood clots (thromboembolism): - swelling, warmth, pain or redness – these symptoms may be signs of a blood clot in a vein near the surface of the skin, - headache, numbness in your face, eye pain or swelling or vision impairment – these symptoms may be signs of a blood clot in a vein behind your eye, - blackening of the skin – this symptom may be a sign of severe damage to the skin tissue.

    Stop using Hemlibra and activated prothrombin complex concentrate (aPCC) (FEIBA) and talk to a doctor immediately if you or your caregiver notices any of the side effects listed above.

    Other side effects when using Hemlibra

    Frequent:

    • headache
    • joint pain
    • a reaction in the area the injection was given (redness, itching, pain)
    • fever
    • muscle aches
    • diarrhoea
    • thrombotic microangiopathy (damage to blood vessels)
    • itchy rash or hives (urticaria)
    • rash

    Less frequent:

    • blood clot in a vein behind your eye (cavernous sinus thrombosis)
    • severe damage of the skin tissue (skin necrosis)
    • blood clot in a vein near the surface of the skin (superficial thrombophlebitis)
    • swollen face, tongue and/or throat and/or difficulty in swallowing, or hives, together with difficulty in breathing which are suggestive of an angioedema
    • allergic reaction

    If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.

    Reporting of side effects

    If you get side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects to SAHPRA via Med Safety APP (Medsafety X SAHPRA) and eReporting platform (who-umc.org) found on SAHPRA website. By reporting side effects, you can help provide more information on the safety of Hemlibra.

    5. How to store Hemlibra

    • Store all medicines out of reach of children.
    • Store vial in a refrigerator at 2 °C - 8 °C.
    • Do not freeze. Do not shake.
    • Keep vial in the outer carton in order to protect from light.
    • Do not use Hemlibra after the expiry date (EXP) shown on the pack.
    • Once removed from the refrigerator, unopened vials can be kept at room temperature (below 30 °C) for up to 7 days.
    • After storage at room temperature, unopened vials may be returned to the refrigerator. Cumulative storage time at room temperature should not exceed 7 days.
    • Once transferred from the vial to the syringe Hemlibra should be used immediately.
    • Return all unused medicine to your pharmacist.
    • Do not dispose of unused medicine in drains or sewerage systems (e.g toilets).
    Important Disclaimer

    The Hemlibra ® 30 mg/1 ml Solution professional information leaflet below is the property of Roche Products and is provided on Somayeza exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Somayeza serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

    Unlock Exclusive Features

    To ensure the fastest, most secure experience, this feature is exclusively available on the free Somayeza mobile app.

    Download the App to Unlock
    On This Page
    Hemlibra ® 30 mg/1 ml Solution
    1/-
    Official PDF leaflet

    The patient information text is available above. Load the original PDF only when you need it.

    Somayeza AI
    Hello! I am your medical reading assistant. What would you like to know about this patient information leaflet?
    Successfully Stashed! 💊

    This patient information leaflet has been safely stored in your digital medical cabinet. No prescription needed to view it later!

    View My Favourites